ArticleBMC cancer2011
Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
Article in BMC cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis.PLoS medicine · 2014Pooled it
- N-3 Long Chain Fatty Acids Supplementation, Fatty Acids Desaturase Activity, and Colorectal Cancer Risk: A Randomized Controlled Trial.Nutrition and cancer · 2022Trial
- Survival outcomes by molecular subtypes based on receptor status in medullary breast carcinoma: a SEER database analysis.Translational cancer research · 2026Article
- Breast cancer clustering integrating complete gene expression profiles and genetic ancestry.PloS one · 2026Article
- Integrative Machine Learning Model for Overall Survival Prediction in Breast Cancer Using Clinical and Transcriptomic Data.Biology · 2025Article
- Deep learning and radiomics integration of photoacoustic/ultrasound imaging for non-invasive prediction of luminal and non-luminal breast cancer subtypes.Breast cancer research : BCR · 2025Article
- Article
- Uncovering subtype-specific metabolic signatures in breast cancer through multimodal integration, attention-based deep learning, and self-organizing maps.Scientific reports · 2025Article
- Molecular Subtypes of Breast Cancer in Arab Women: Distribution and Prognostic Insights.Journal of epidemiology and global health · 2025Article
- Analysis of dynamic contrast-enhanced T1-weighted imaging parameters in type II TIC breast lesions.Frontiers in oncology · 2025Article
- Dynamic contrast-enhanced magnetic resonance imaging radiomics analysis based on intratumoral subregions for predicting luminal and nonluminal breast cancer.Quantitative imaging in medicine and surgery · 2023Article
- Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia.Frontiers in endocrinology · 2023Article
- The role of mineralocorticoids and glucocorticoids under the impact of 11β-hydroxysteroid dehydrogenase in human breast lesions.Medical molecular morphology · 2022Article
- Article
- Association between lincRNA expression and overall survival for patients with triple-negative breast cancer.Breast cancer research and treatment · 2021Article
- Clinical and X-ray characteristics for expressions of different receptors in patients with breast cancer.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- High Prevalence of Triple-Negative Breast Cancer in Southern Shaanxi Province, China.Cancer management and research · 2021Article
- Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.Breast cancer research and treatment · 2020Article
- Pyrrolo [3,4-Aging · 2020Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundMolecular classification of breast cancer is an important prognostic factor. The distribution of molecular subtypes of breast cancer and their prognostic value has not been well documented in Asians.
methodsA total of 2,791 breast cancer patients recruited for a population-based cohort study were evaluated for molecular subtypes of breast cancer by immunohistochemical assays. Data on clinicopathological characteristics were confirmed by centralized pathology review. The average follow-up of the patients was 53.4 months. Overall and disease-free survival by molecular subtypes of breast cancer were evaluated.
resultsThe prevalence of the luminal A, luminal B, human epidermal growth factor receptor 2 (HER2), and triple-negative subtypes were 48.6%, 16.7%, 13.7%, and 12.9%, respectively. The luminal A subtype was more likely to be diagnosed in older women (P = 0.03) and had a stronger correlation with favorable clinicopathological factors (smaller tumor size, lower histologic grade, and earlier TNM stage) than the triple-negative or HER2 subtypes. Women with triple-negative breast cancer had a higher frequency of family history of breast cancer than women with other subtypes (P = 0.048). The 5-year overall/disease-free survival percentages for the luminal A, luminal B, HER2, and triple-negative subtypes were 92.9%/88.6%, 88.6%/85.1%, 83.2%/79.1%, and 80.7%/76.0%, respectively. A similar pattern was observed in multivariate analyses. Immunotherapy was associated with improved overall and disease-free survival for luminal A breast cancer, but reduced disease-free survival (HR = 2.21, 95% CI, 1.09-4.48) for the HER2 subtype of breast cancer.
conclusionsThe triple-negative and HER2 subtypes were associated with poorer outcomes compared with the luminal A subtype among these Chinese women. The HER2 subtype was more prevalent in this Chinese population compared with Western populations, suggesting the importance of standardized HER2 detection and anti-HER2 therapy to potentially benefit a high proportion of breast cancer patients in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.